Testicular cancer: Clinical practice guidelines

Robert J. Motzer; Robert R. Bahnson; Barry Boston; Michael A. Carducci; Mayer Fishman; Steven L. Hancock; Ralph J. Hauke; Gary R. Hudes; Philip Kantoff; Timothy M. Kuzel; Paul H. Lange; Ellis G. Levine; Chris Logothetis; Kim A. Margolin; Bruce G. Redman; Sylvia Richey; Cary N. Robertson; Wolfram E. Samlowski; Joel Sheinfeld; Donald A. Urban

Testicular cancer: Clinical practice guidelines

Robert J. Motzer^*, Robert R. Bahnson, Barry Boston, Michael A. Carducci, Mayer Fishman, Steven L. Hancock, Ralph J. Hauke, Gary R. Hudes, Philip Kantoff, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Chris Logothetis, Kim A. Margolin, Bruce G. Redman, Sylvia Richey, Cary N. Robertson, Wolfram E. Samlowski, Joel Sheinfeld, Donald A. Urban

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Ninety five percent of malignant tumors arising in the testes are germ cell tumors (GCTs). Although GCTs are relatively uncommon tumors, comprising only 2% of all human malignancies, they constitute the most common solid tumor in men between 15 and 34. Additionally, the worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCT are cured, but a delay in diagnosis can correlate with a higher stage at presentation. Standard therapy has been developed for essentially all stages of management and must be closely followed to ensure the potential for cure.

Original language	English (US)
Pages (from-to)	52-76
Number of pages	25
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	3
Issue number	1
State	Published - Jan 2005

Keywords

Alpha-fetoprotein
Cisplatin
Germ cell tumors
Human chorionic gonadotropin
Lactate dehydrogenase
NCCN Clinical Practice Guidelines
Nonseminoma
Seminoma
Testicular cancer

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Motzer, R. J., Bahnson, R. R., Boston, B., Carducci, M. A., Fishman, M., Hancock, S. L., Hauke, R. J., Hudes, G. R., Kantoff, P., Kuzel, T. M., Lange, P. H., Levine, E. G., Logothetis, C., Margolin, K. A., Redman, B. G., Richey, S., Robertson, C. N., Samlowski, W. E., Sheinfeld, J., & Urban, D. A. (2005). Testicular cancer: Clinical practice guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 3(1), 52-76.

@article{f76114a9dea84f91ace1ad33b38fa30e,

title = "Testicular cancer: Clinical practice guidelines",

abstract = "Ninety five percent of malignant tumors arising in the testes are germ cell tumors (GCTs). Although GCTs are relatively uncommon tumors, comprising only 2% of all human malignancies, they constitute the most common solid tumor in men between 15 and 34. Additionally, the worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCT are cured, but a delay in diagnosis can correlate with a higher stage at presentation. Standard therapy has been developed for essentially all stages of management and must be closely followed to ensure the potential for cure.",

keywords = "Alpha-fetoprotein, Cisplatin, Germ cell tumors, Human chorionic gonadotropin, Lactate dehydrogenase, NCCN Clinical Practice Guidelines, Nonseminoma, Seminoma, Testicular cancer",

author = "Motzer, {Robert J.} and Bahnson, {Robert R.} and Barry Boston and Carducci, {Michael A.} and Mayer Fishman and Hancock, {Steven L.} and Hauke, {Ralph J.} and Hudes, {Gary R.} and Philip Kantoff and Kuzel, {Timothy M.} and Lange, {Paul H.} and Levine, {Ellis G.} and Chris Logothetis and Margolin, {Kim A.} and Redman, {Bruce G.} and Sylvia Richey and Robertson, {Cary N.} and Samlowski, {Wolfram E.} and Joel Sheinfeld and Urban, {Donald A.}",

year = "2005",

month = jan,

language = "English (US)",

volume = "3",

pages = "52--76",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "1",

}

Motzer, RJ, Bahnson, RR, Boston, B, Carducci, MA, Fishman, M, Hancock, SL, Hauke, RJ, Hudes, GR, Kantoff, P, Kuzel, TM, Lange, PH, Levine, EG, Logothetis, C, Margolin, KA, Redman, BG, Richey, S, Robertson, CN, Samlowski, WE, Sheinfeld, J & Urban, DA 2005, 'Testicular cancer: Clinical practice guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 1, pp. 52-76.

TY - JOUR

T1 - Testicular cancer

T2 - Clinical practice guidelines

AU - Motzer, Robert J.

AU - Bahnson, Robert R.

AU - Boston, Barry

AU - Carducci, Michael A.

AU - Fishman, Mayer

AU - Hancock, Steven L.

AU - Hauke, Ralph J.

AU - Hudes, Gary R.

AU - Kantoff, Philip

AU - Kuzel, Timothy M.

AU - Lange, Paul H.

AU - Levine, Ellis G.

AU - Logothetis, Chris

AU - Margolin, Kim A.

AU - Redman, Bruce G.

AU - Richey, Sylvia

AU - Robertson, Cary N.

AU - Samlowski, Wolfram E.

AU - Sheinfeld, Joel

AU - Urban, Donald A.

PY - 2005/1

Y1 - 2005/1

N2 - Ninety five percent of malignant tumors arising in the testes are germ cell tumors (GCTs). Although GCTs are relatively uncommon tumors, comprising only 2% of all human malignancies, they constitute the most common solid tumor in men between 15 and 34. Additionally, the worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCT are cured, but a delay in diagnosis can correlate with a higher stage at presentation. Standard therapy has been developed for essentially all stages of management and must be closely followed to ensure the potential for cure.

AB - Ninety five percent of malignant tumors arising in the testes are germ cell tumors (GCTs). Although GCTs are relatively uncommon tumors, comprising only 2% of all human malignancies, they constitute the most common solid tumor in men between 15 and 34. Additionally, the worldwide incidence of these tumors has more than doubled in the past 40 years. More than 90% of all patients diagnosed with GCT are cured, but a delay in diagnosis can correlate with a higher stage at presentation. Standard therapy has been developed for essentially all stages of management and must be closely followed to ensure the potential for cure.

KW - Alpha-fetoprotein

KW - Cisplatin

KW - Germ cell tumors

KW - Human chorionic gonadotropin

KW - Lactate dehydrogenase

KW - NCCN Clinical Practice Guidelines

KW - Nonseminoma

KW - Seminoma

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=33747627379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747627379&partnerID=8YFLogxK

M3 - Review article

C2 - 19813323

AN - SCOPUS:33747627379

SN - 1540-1405

VL - 3

SP - 52

EP - 76

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Testicular cancer: Clinical practice guidelines

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this